TomTec's 3-D ultrasound technology lives on. The defunct ultrasound developer has sold rights to the technology to a group of managers from the company's German subsidiary in Munich. The executives have formed a new company, TomTec GmbH, with the
TomTec's 3-D ultrasound technology lives on. The defunct ultrasound developer has sold rights to the technology to a group of managers from the company's German subsidiary in Munich. The executives have formed a new company, TomTec GmbH, with the intention of carrying forward TomTec's 3-D legacy.
TomTec Imaging Systems closed its doors last month after its venture-capital backers pulled out of the company and its management failed to find new funding (SCAN 6/11/97). In liquidating the company, TomTec's management said it intended to sell off the company's assets.
The Munich-based management team includes Bernhard Mumm, Frank Schlau, and Ulrich Haupt, who intend to resume on a worldwide basis all of the 3-D business activities and end-user relationships of TomTec Imaging Systems. The Munich facility had been the headquarters of TomTec predecessor Tomographic Technologies, which was merged with Prism Imaging/Freeland Systems to create TomTec Imaging Systems in late 1993.
All of TomTec's 3-D products, including TomTec Echo-Scan, EchoView, and Compact 3-D, will continue to be produced and marketed. TomTec GmbH will also continue the development of Windows NT-based clinical procedure and visualization packages for cardiac and general imaging applications.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.